United States of America
Tim Kutzkey, Ph.D., is the Chairman of Nurix’s board of directors and also serves as the Interim President. He is a Partner at The Column Group and has contributed to the conception, formation and launch of several portfolio companies. He formerly was a scientist at KAI Pharmaceuticals, where his research focused on cell assay and pharmacodynamic marker development for selective protein kinase C inhibitors. Prior to KAI, Dr. Kutzkey studied at the University of California, Berkeley as a graduate student and postdoctoral scholar in the lab of Dr. Robert Tjian. He completed his Ph.D. on the biochemistry and genetics of long-range gene regulatory mechanisms. Dr. Kutzkey completed his undergraduate education at Stanford University.